Nurix Therapeutics, Inc. (NRIX) Stock Forecast
NRIX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 14 analysts
- Price target
- $34.50 average of analyst targets
- Upside to target
- +41.3% from the latest close
- Next earnings
- —
- 52-week range
- $10.39 – $27.79
NRIX analyst ratings
14 analystsNumber of analysts at each rating.
NRIX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NRIX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Aug '26) | $5.11 | $4.29 | $5.74 | −$1.03 | +596.5% | 3 |
| Next quarter (Feb '27) | −$0.59 | −$0.59 | −$0.59 | −$0.79 | +25.3% | 1 |
| Current fiscal year (FY2026) | $3.02 | $2.96 | $3.10 | −$3.05 | +199.0% | 3 |
| Next fiscal year (FY2027) | −$1.28 | −$2.48 | −$0.62 | $3.02 | −142.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NRIX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Aug '26) | $706.8M | $700.0M | $713.6M | +8,853.4% | 2 |
| Next quarter (Feb '27) | $15.0M | $15.0M | $15.0M | +139.9% | 1 |
| Current fiscal year (FY2026) | $744.8M | $704.0M | $785.2M | +786.9% | 4 |
| Next fiscal year (FY2027) | $123.2M | $58.0M | $200.0M | −83.5% | 4 |
NRIX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NRIX revenue: reported and forecast
NRIX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Aug '26) | −$0.61 | $5.11 | $5.11 | $5.11 | $5.11 | −932.9% | 2 up · 0 down |
| Next quarter (Feb '27) | −$0.57 | −$0.44 | −$0.44 | −$0.44 | −$0.59 | +3.1% | 4 up · 0 down |
| Current fiscal year (FY2026) | −$2.72 | $1.79 | $3.38 | $3.38 | $3.02 | −211.2% | 2 up · 1 down |
| Next fiscal year (FY2027) | −$2.21 | −$1.44 | −$1.07 | −$1.07 | −$1.28 | −42.3% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NRIX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NRIX beat in 7 of 12.
What analysts expect from NRIX
14 analysts cover Nurix Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $34.50, 41.3% above the latest close of $24.42. Analysts expect earnings of $3.02 per share for FY2026, +199.0% from a year earlier. For FY2027 the average estimate is −$1.28 per share on revenue of $123.2 million. Nurix Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: NRIX income statement, NRIX key metrics, NRIX chart. See the NRIX stock overview for the latest quote and news.
NRIX forecast FAQ
What is Nurix Therapeutics's price target?
The average analyst price target for Nurix Therapeutics is $34.50, 41.3% above the latest close of $24.42.
Is Nurix Therapeutics a buy, hold or sell?
Of 14 analysts covering Nurix Therapeutics, 8 rate it a strong buy, 5 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nurix Therapeutics's EPS forecast?
Analysts forecast $3.02 per share for FY2026 (range $2.96 to $3.10); for FY2027 the estimate is −$1.28.
What is Nurix Therapeutics's revenue forecast?
The average revenue estimate for FY2026 is $744.8 million, growth of 786.9%; for FY2027 it is $123.2 million.
Does Nurix Therapeutics usually beat earnings estimates?
Nurix Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.